HCW Biologics Regains Nasdaq Compliance After Announcing 1-For-6 Reverse Stock Split, Effective June 30
HCW Biologics Inc. (the "Company" or "HCW Biologics") (Nasdaq: HCWB ), a U.S.-based clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation, focusing on autoimmune disorders and other inflammatory diseases, cancer and sen